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isolates of methicillin-resistant Staphylococcus
aureus in Jakarta, Indonesia
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Background: Community Acquired Methicillin Resistant Staphylococcus aureus (CA-MRSA) is a strain of MRSA that
can cause infections in patients in the community, in which these patients had no previous risk factors for MRSA
infection and the patient received 72 hours prior to infection when admitted to hospital. This study aims to
determine and compare the characteristics of epidemiological, clinical, and molecular biology of CA-MRSA with
HA-MRSA.
Methods: A total of 11 clinical strains of Methicillin-resistant Staphylococcus aureus (MRSA) and Methicillin-sensitive
Stapylococcus aureus (MSSA) were collected from 2 hospitals in Jakarta, Indonesia in 2012. SCCmec typing was
performed by multiplex polymerase chain reaction (PCR) and the presence of six genes (vraR, vraG, vraA, vraF,fruA,
and fruB) associated with vancomycin resistance was examined by simple PCR analysis.
Results: We found three strains of community-acquired MRSA with SCCmec type II and one strain of hospital-
acquired MRSA with SCCmec type IV. The other seven strains did not contain mecA genes and SCCmec. Plasmid
pUB110 was found in one strain of community-acquired MRSA and two strains of hospital-acquired MRSA. vraA
genes were present in 9 of the 11 strains, vraF in 4, vraG in 5, and vraR in 4. Note worthily, three quarters of strains
without pUB110 contained vraR and vraF, and 70% contained vraA, whereas 60% of strains with pUB110 contained
vraG.
Conclusion: Based on these results, we should be concerned about the possibility of transition from MRSA strains
sensitive to vancomycin in VISA strains of MRSA strains obtained in clinical trials. But first we need to look the
existence of natural VISA or hVISA among these MRSA strains.Background
Staphylococcus aureus (S. aureus) causes a wide variety
of infections with clinical symptoms ranging from mild
skin infections to severe deep infections. One of the im-
portant strains frequently found among nosocomial in-
fections is Methicillin-resistant Staphylococcus aureus
(MRSA) [1]. Data from the previous study showed
higher prevalence and variations of MRSA in countries
of the Asia-Pacific region than in Europe [2]. In some
countries, such as Korea, Hong Kong, and Japan, the* Correspondence: hattaram@indosat.net.id
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reproduction in any medium, provided the orprevalence even exceeded 70% of all S. aureus isolated
from hospitalized patients [3-6].
MRSA is resistant to methicillin and other related β-
lactam antibiotics, such as cefoxitin and oxacillin [1].
Initially, MRSA infections were associated only with
infection exposure in health care and hospital settings,
and were therefore referred to as Hospital-acquired
MRSA (HA-MRSA) [7]. Two decades ago, Community-
acquired MRSA (CA-MRSA) started to emerge among
MRSA isolates from individuals with no or minimal ex-
posure to health care facilities [8,9]. Currently, this strain
tends to be more common among S. aureus infections
as it is increasingly reported, particularly among children
and young adults [8-11]. CA-MRSA strains are roughly
classified into two main groups. The first group consists
of CA-MRSA strains that are resistant to mono beta-al Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fect healthy patients who are not predisposed to MRSA
[12]. The second group consists of MRSA strains iso-
lated from individuals who have risk factors for infection
[13]. Clinically, the CA-MRSA strains can be isolated
from severe infections such as osteomyelitis, bacteremia,
endocarditis, and pneumonia [14-17].
The rapid evolvement and continuous spread of new
MRSA strains may due to their capability to acquire and
to use antimicrobial resistance genes encoded by mobile
genetic elements such as Staphylococcal cassette chro-
mosome mec (SCCmec)[18-21]. SCCmec is a mobile
genetic element which harbors the methicillin resistance
gene mecA [22]. Based on mec and ccr gene complex
variations, there are 11 SCCmec types have been de-
scribed so far, and also some subtypes or sub variations
have been identified [20,23-25]. Interestingly these
genotype variations also reflected their antimicrobial char-
acteristic [26]. SCCmec types I-III are associated with HA-
MRSA isolates, while types IV and V have been found
related to CA-MRSA [26,27]. A previous study reported
that up to 80% of MRSA isolates were of sequence type 22-
MRSA-SCCmec type IV (ST22-MRSA-IV) [28].
Several reports have indicated the possibility that the
incidence of CA-MRSA infection would surpass that of
HA-MRSA infection [16,29,30]. Considering the wide
spread of CA-MRSA in Asian countries in particular,
there is an urgent need of epidemiological or molecular
studies of this strain to guide targeting of effective thera-
peutic agents. In the present study, therefore, we studied
the molecular variation of MRSA isolates obtained from
two hospitals in Jakarta in the year 2012. We found that
SCCmec type II was the predominant SCCmec type
among these clinical isolates. As the main therapy for
MRSA, vancomycin may contribute to the emergence
of a vancomycin-intermediate S. aureus (VISA) strain.
As previously reported, VISA can emerge from aTable 1 Characteristics of clinical samples with SCCmec typin
antibiotics
Sample Specimens SCCmec pUB 110 SXT C
4 Urine IV + R S
9 Sputum II + R R
11 Throat swab II + R R
10 Pus II - R R
1 Blood - - S S
2 Blood - - S S
3 Bronchial discharge - - R S
5 Blood - - R S
6 Urine - - S S
7 Urine - - S S
8 Urine - - S Svancomycin susceptible S. aureus (VSSA) strain during
chronic infection – but the genetic factors tcontributing
to this phenomenon still need to be further defined
[31-34]. Therefore we also studied certain VISA gene
variations of these strains.
Methods
Bacterial strains
A total of 11 clinical strains of S. aureus were collected
in 2012 from two hospitals in Jakarta: RSAB Harapan
Kita and Siloam Kebun Jeruk, Indonesia (Table 1). Only
one strain per patient was included. Isolates of S.aureus
colonies were identified on the basis of pigments and
clotting factors. Zone barriers were determined on
Mueller-Hinton agar according to the Clinical and la-
boratory standards institute (CLSI) guidelines. Strains
were incubated at 35º for 18 hours then the diameter of
inhibition zone was determined. Amoxicillin clavulanate,
cefuroxime, ceftriaxone, cefotaxime, ceftazidime, cefepime,
imipenem, cotrimoxazole, clindamycin, amikacin, ciproflox-
acin, levofloxacin, vancomysin, linezolid, teicoplanin, tige-
cyclin, and fosfomycin were tested. Breakpoint for the
definition of antibiotic resistance in S. aureus was based on
CDC guidelines manual.
Genomic DNA isolation
Total genomic DNA was isolated using the WizardW
genomic DNA purification kit (Promega corporation,
Madison, WI, USA).
Multiplex PCR for SCCmec typing
Multiplex PCR included eight loci (A through H) se-
lected on the basis of mec element sequences described
in previous reports [35]. And the primers have been de-
scribed on previous reports (Table 2) [36,37]. PCR was
performed on a volume of 50 mL using a Gene Amp
PCR kit (Applied Biosystems, New Jersey, USA) and ag, plasmid pUB110 and the sensitivity of non beta-lactam
C AN CIP LVFX VA TEC TGC FOS LZ
S S S S S S S S
S R R S S S R S
S R R S S S R S
S R R S S S R S
S S S S S S S S
S S S S S S S S
S S S S S S R S
S S S S S S R S
S S S S S S S S
S S S S S S S S
S S S S S S S
Table 2 Primers used in multiplex PCR for SCCmec typing
Locus Name Oligonecleotide sequence (5’-3) Amplicon size (bp) Specificity (SCCmectype)
A CIF2 F2 TTCGAGTTGCTGATGAAGAAGG 495 I
CIF2 R2 ATTTACCACAAGGACTACCAGC
B KDP F1 AATCATCTGCCATTGGTGATGC 284 II
KDP R1 CGAATGAAGTGAAAGAAAGTGG
C MECI P2 ATCAAGACTTGCATTCAGGC 209 II, III
MECI P3 GCGGTTTCAATTCACTTGTC
D DCS F2 CATCCTATGATAGCTTGGTC 342 I, II, IV
DCS R1 CTAAATCATAGCCATGACCG
E RIF4 F3 GTGATTGTTCGAGATATGTGG 243 III
RIF4 R9 CGCTTTATCTGTATCTATCGC
F RIF5 F10 TTCTTAAGTACACGCTGAATCG 414 III
RIF5 R13 GTCACAGTAATTCCATCAATGC
G IS431 P4 CAGGTCTCTTCAGATCTACG 381 pUB11C
Pub110 R1 GAGCCATAAACACCAATAGCC
H IS431 P4 CAGGTCTCTTCAGATCTACG 303 III
pT181 R1 GAAGAATGGGGAAAGCTTAC
mecA MECA P4 TCCAGATTACAACTTCACCAGG 162 Positive control
MECA P7 CCACTTCATATGTTGTAGG
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(each) deoxynucleoside triphosphate; 400 nM primer
CIF2 F2, CIF2 R2, MECI P2, P3 MECI, RIF5 F10, RIF5
R13, R1 pUB110, and pT181 R1; 800 nM primer F2
DCS, DCS R2, P4 MECA, MECA P7 and P4 IS431; 200
nM primers KDP F1, KDP R1, RIF4 F3, and RIF4 R9;
1.25 U Ampli Taq, and approximately 5 ng of DNA tem-
plate. The ASTEC program temperature control system
PC-701 DNA thermo cycler was programmed as follows:
10 min at 95°C, 30 cycles of 30 seconds at 94°C, 30 -
seconds at 53°C, and 1 min at 72°C, and 10 minutes at
72°C. Samples were stored at 4°C until analysis. Ten-mL
aliquot of the PCR products electrophoresed on 2%
agarose gel (contained ethidium bromide) for 30 minutes
at 100 V. Gel then photographed under ultraviolet light.
PCR analysis of genes related to VISA
Six genes associated with VISA strains, vraR, vraG, vraA,
vraF, fruA,and fruB, were selected for PCR analysis [38].
PCR amplification was performed using primersTable 3 Primers used in PCR analysis of VISA-related genes






fruB ABO35449 5’-AGATGTTGAGTCAdesigned from the published NCBI sequence (Table 3).
PCR reaction was performed in 13 ml reaction mixture
containing 10 mM Tris (pH 8.3), 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM each deoksinucleotide triphosphate,
0.5 mM of each primer, and 2.5 U Taq DNA polymerase
(Applied Biosystems, NewJersey, USA). The ASTEC pro-
gram temperature control systemPC-701 DNA thermo
cycler was programmed as follows: 10 min at 95°C, 30 -
cycles of 1 min at 94°C, 1 min at 58°C, and 1 min at
72°C, and 10 minutes at 72°C. Samples were stored at
4°C until analysis. Ten ml aliquot of the PCR product
was electrophorese don agarose gel 1.5% for 30 min at
100 V. Gels were stained with ethidium bromide and
photographed under ultraviolet light. Mu50 (ATCC; 700
699) was used as a positive control.
Ethical considerations
The project received ethical approval from the review
board of the Department of National Education of the
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the procedure and the purpose of the study. Oral in-
formed consent was applied as the collection of the
specimens did not affect the intervention procedure to
any extend and all clinical data was made anonymous
before analysis. The collection of informed consent was
witnessed by a nurse and or the medical officer in charge
and was recorded on the medical file of the patient. The
verbal consent procedure was approved by the ethical
committee.Results
MRSA and MSSA strains
Of the 11 S. aureus isolates from 2012 analyzed, 5 were
CA-MSSA, 2 HA-MSSA, 1 CA-MRSA and 3 HA-MRSA
. The 4 MRSA isolates (CA-MRSA and HA-MRSA) were
derived from different clinical samples, i.e. urine, spu-
tum, pus, and throat swab. Sensitivity testing showed
that all isolates (both MSSA and MRSA) had good sensi-
tivity to vancomycin, teicoplanin, linezolid, tigecycline,
and amikacin. Clindamycin was still sensitive for CA-
MSSA, HA-MSSA and CA-MRSA.SCCmec typing
SCCmec typing revealed that 3 of the 4 MRSA isolates
contained SCCmec type II; the other 1 contained
SCCmec type IV. Three of all 11 strains contained plas-
mid pUB110. Figure 1 shows the banding patterns of the
products obtained by multiplex PCR for SCCmec typing.
Four strains showed the 162-bp fragment of the mecA
gene. Type II strains displayed the 284-bp fragment,
209-bpfragment, and a 342-bp fragment with or without
a381-bp fragment from the plasmid pUB110; Strain type
IV showed the342-bp fragment without the381-bp frag-
ment from the plasmid pUB110.Figure 1 The results of multiplex PCR SCCmec gene typing in MRSA aThe presence of genes associated VISA
The following six genes were studied: vraR, vraG, vraA,
vraF, fruA, and fruB. Ten of the 11 S. aureus isolates
contained vraA, 4 vraF, 5 vraG, and 4 vraR (Figure 2,
Table 4). All 11 isolates contained fruA and 7 contained
fruB. Mu50 strain was used as positive control con-
tained all six genes. 30% of MRSA strains with pUB110
contained vraA genes, 60% vraG, 25% vraR, and
25% vraF.
Discussion
In this study we found that three (27%) of our 11 S.
aureus strains contained genes mecA and SCCmec type
II, and 1 (9%) contained SCCmec type IV. Previous ex-
amined the study examined SCCmec types of 138 MRSA
strains isolated in Japan in 1999 and found that 126
(91.3%) contained SCCmec type II, 6 (4.3%) contained
SCCmec type I, and 5 (3.6%) contained SCCmec type IV
[39]. The results of this research in Japan combined with
the findings in this study suggest that type II SCCmec
occurs frequently in Asia pacific region. Types I and III
SCCmec were not detected in this study. However, type
III SCCmec has been reported in European countries,
Australia, New Zealand, Thailand, Vietnam, Singapore,
the Philippines, and elsewhere [40,41].
In addition to the structural classification of four types
of SCCmec, we also checked the presence of plasmid
pUB110 in SCCmec. Only 3 strains (27%) contained
plasmid pUB110. MRSA has been known to cause noso-
comial infections. MRSA infections have been reported
increased cases among the group of patients without any
real connection with the hospital [42]. CA-MRSA strains
have been reported in Australia [43,44], New Zealand
[45], England [46], Canada [47], and the United States
[41].
In this study we found fruA in all 11 strains and fruB
in 7 of all strains (64%). Gen vraA considered as a longnd MSSA.
Figure 2 The results of multiplex PCR VISA gene in MRSA and MSSA.
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ABC transporter genes. These genes are up-regulated in
the VISA (Mu50) and may contribute to resistance to
vancomycin [48]. Furthermore, vancomycin resistance is
thought to be caused by increased cell wall synthesis
[38]. The system settings are vraSR new response has
been reported, and vraR, which is one of two compo-
nents of the system, seems to play a role in vancomycin
resistance. As a result of the introduction of genes into
cells, vraR sensitive vancomycin will increase the level of
resistance to vancomycin [38]. In the present study it
was found that all four MRSA isolates were sensitive to
vancomycin, and that one of these contained the vraR
gene. The finding of this VISA related gene in
vancomycin-sensitive among MRSA strains may indi-
cates the possible risk of transition from MRSA to VRSA
but first we need to rule out the possibility of VISA or
hVISA are exist among our MRSA strain. Something
lacked on this study.Table 4 Characterization specimens and their related to VISA
SPECIMENS No. MRSA/MSSA pUB 100
Blood 1 HA-MSSA -
Blood 2 CA-MSSA -
Bronchial discharge 3 HA-MSSA -
Urine 4 CA-MRSA +
Blood 5 CA-MSSA -
Urine 6 CA-MSSA -
Urine 7 CA-MSSA -
Urine 8 CA-MSSA -
Sputum 9 HA-MRSA +
Pus 10 HA-MRSA -
Throat swab 11 HA-MRSA +
TOTAL 11 11 27%Note worthily, we found that three of the four MRSA
strains contained plasmid pUB110, which most likely is
a strain of CA-MRSA, because it only one contained
genes of vraF and vraR at relatively lower frequencies
than the MRSA strains containing plasmid pUB110, but
contained no genes of vraR and vraF. Therefore, we
need to further investigate the relationship between
SCCmec typing, as a means to identify the genetic back-
ground of the bacteria, as well as the presence of genes
associated VISA.
Conclusion
Most strains of MRSA: 75% (3/4) contains a Type II
SCCmec, and only 1(25%) strain containing SCCmec
type IV and the overall of S.aureus isolates containing all
six genes associated VISA with different frequencies. In
particular, the strain that is considered as CA-MRSA,
the strain is considered to contain vraR, at 1 CA-MRSA
strain was found not to contain vraR and only 33% (1/3)genes and pUB-110
VraA vraG vraF vraR fruA fruB
+ - + + + +
+ - - - + +
+ - - - + +
+ + - - + -
+ - + + + +
+ - + + + +
- + - - + -
+ - - - + +
+ + + + + +
+ + - - + -
+ + - - + -
91% 45% 36% 36% 100% 64%
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http://www.biomedcentral.com/1756-0500/6/110of vraR genes containing in HA-MRSA strains. Based on
these results, we should be concerned about the possibil-
ity of transition from MRSA strains sensitive to vanco-
mycin in VISA strains of MRSA strains obtained in
clinical trials. But first we need to look the existence of
natural VISA or hVISA among these MRSA strains.
In this study, we applied the multiplex PCR test to de-
termine the type of SCCmec, and a simple PCR test to
detect the presence of genes related to VISA. Both tests
can be easily and rapidly performed at many hospitals
and laboratories, and can therefore be considered useful
tools for the investigation of clinical MRSA strains.
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